Excellent Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children and Adolescents with Acquired Severe Aplastic Anemia  by Im, Ho Joon et al.
Biol Blood Marrow Transplant 19 (2013) 754e759American Society for Blood
ASBMT
and Marrow TransplantationExcellent Outcome of Haploidentical Hematopoietic Stem
Cell Transplantation in Children and Adolescents
with Acquired Severe Aplastic Anemia
Ho Joon Im 1,*, Kyung Nam Koh 1, Eun Seok Choi 1, Seongsoo Jang 2,
Seog Woon Kwon 2, Chan-Jeoung Park 2, Hyun-Sook Chi 2, Jong Jin Seo 1
1Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center
Children’s Hospital, Seoul, Korea
2Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, KoreaArticle history:
Received 17 December 2012
Accepted 28 January 2013
Key Words:
Children and adolescents
Severe aplastic anemia
T cell depletion
Haploidentical stem cell
transplantationFinancial disclosure: See Acknowl
* Correspondence and reprint re
of Pediatric Hematology/Oncology
of Ulsan College of Medicine, Asan
Songpa-gu, Seoul 138-736, Korea.
E-mail address: hojim@amc.seo
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
We evaluated the outcome of children and adolescents with acquired severe aplastic anemia (SAA) who
received haploidentical hematopoietic stem cell transplantation (HHCT) with in vitro T celledepleted
peripheral blood stem cells. Twelve patients with acquired SAA received a total of 15 HHCTs with in vitro
CD3-depleted grafts between July 2009 and July 2012. Among the 12 patients, 11 achieved neutrophil
engraftment at a median of 10 days (range, 9 to 13 days) after HHCT. One patient failed to achieve primary
engraftment, and two experienced graft rejection soon after engraftment. All three patients who experienced
early graft failure received a second HHCT and achieved sustained engraftment. Thus, the ﬁnal engraftment
rate was 100%. Acute graft-versus-host disease was assessed in 9 patients, excluding the 3 patients with early
graft failure. Three of these patients developed acute graft-versus-host disease (two  grade II and one with
grade III). All 12 patients survived and were transfusion-independent at a median follow-up of 14.3 months
(range, 4.1 to 40.7 months). Hematopoietic stem cell transplantation from haploidentical family donors with
in vitro CD3 T cell depletion is a reasonable therapeutic option for children and adolescents with acquired
SAA. Our future trial with a uniform protocol will help to solve the problems associated with HHCT and
provide a valuable platform for the further development of HHCT as a therapy for SAA.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION donor. In addition, delayed immune recovery and a high
Severe aplastic anemia (SAA) is a life-threatening disorder
for which allogeneic hematopoietic stem cell transplantation
(HCT) is the currently available curative treatment. Alloge-
neic HCT from a matched sibling donor is the standard
frontline therapy. However, immunosuppressive therapy
(IST) is widely used for patients who lack a matched sibling
donor before considering HCT from an unrelated donor [1,2].
With the advances in human leukocyte antigen (HLA) typing
techniques, HCT from a well-matched unrelated donor can
be offered to patients, particularly children and adolescents
with no suitable related donors and who are refractory to IST
[3]. However, treating patients who lack a suitable related or
unrelated donor is quite challenging.
HCT using cord blood or a haploidentical related donor is
a possible alternative for patients lacking a matched suitable
donor. Both cord blood and haploidentical related donor
have the advantages of prompt use. In addition, a hap-
loidentical donor has additional beneﬁts of donor availability
in almost all patients and later use of donor cells after
transplantation. However, the high rate of graft failure (GF)
and refractory graft-versus-host disease (GVHD) are major
drawbacks to the universal use of haploidentical hemato-
poietic stem cell transplantation (HHCT) for patients who
require transplantation to elicit a cure but lack a suitableedgments on page 758.
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13.01.023incidence of infection continue to be major problems [4,5].
Only a few reports have studied the use of HHCT in chil-
dren with acquired aplastic anemia [6-8]. Most reports used
a T celledepleted strategy to prevent a fatal GVHD. The
earlier studies, using megadoses of CD34-selected stem cells,
reported promising results with rapid engraftment, sug-
gesting that this regimen may be a possible alternative for
children who do not respond to IST and lack a suitable
matched donor. However, HHCT using CD34-selected stem
cells is associated with a high rate of infectious complica-
tions, which are potentially related to delayed immune
recovery [7]. Reports suggest that depleting CD3 cells is
superior to selecting CD34 cells in terms of rapid engraft-
ment and immune reconstitution [9,10]. Depletion of only
CD3þ T cells has the advantage of increasing the number of
natural killer cells, monocytes, and other beneﬁcial cells [11].
Therefore, presenting this study, we used the CD3
depletion method to remove T cells and reduce the incidence
of severe GVHD in an HHCT setting. The early results of our
trial for 4 patients with SAAwho received HHCT with in vitro
CD3-depleted grafts were reported previously [12]. This
study reports the results of this HHCT protocol in a larger
cohort of children and adolescents with acquired SAA, who
all had excellent outcomes.
METHODS
Patients
Between July 2009 and July 2012, 12 patients with acquired SAA
received a total of 15 HHCTs with in vitro CD3-depleted peripheral blood
stem cells. All enrolled patients had negative chromosome breakage test
results, and none had any stigma of dyskeratosis congenita. Patients with
clonal evolution were excluded from this study. None had any evidence of
dyshematopoiesis or chromosomal abnormalities. Nine patients underwentTransplantation.
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but none had the clone. All transplantation protocols were approved by the
Institutional Review Board of Asan Medical Center and were registered at
www.clinicaltrials.gov (NCT01105273). All patients and donors provided
written informed consent.
Conditioning Regimens and GVHD Prophylaxis
Six patients received a conditioning regimen comprising ﬂudarabine
(150 mg/m2), cyclophosphamide (120 mg/kg), and rabbit antithymocyte
globulin (ATG, 7.5 mg/kg), and 6 patients received low-dose total- body
irradiation (LD-TBI, 400 cGy), ﬂudarabine (150 mg/m2), cyclophosphamide
(100 mg/kg), and ATG (7.5 mg/kg). In the ﬁrst 4 patients (cases 1 to 4), ATG
was administered just before the day of stem cell infusion. However,
the remaining 8 patients received ATG at the beginning of conditioning, long
before the day of infusion, due to concern about the possible donor T cell
depleting effects of the proximal ATG. To prevent GVHD, calcineurin inhibi-
tors (cyclosporine in 4 patients and tacrolimus in 8 patients) and mycofe-
nolate mofetil (MMF)were used, starting on the day of peripheral blood stem
cell infusion. MMF was given orally at a dose of 15 mg/kg twice a day and
discontinued on day þ28. Calcineurin inhibitors were continued until day
þ90. After day þ90, the dose of cyclosporine or tacrolimus was gradually
reduced by 5% a week, and the drugs were discontinued at approximately
8 months after grafting if the patient was not under treatment for GVHD.
Stem Cell Collection and Graft Manipulation by T Cell Depletion
All donors received granulocyte colony-stimulating factor for aminimum
of 4 consecutive days, and peripheral blood stem cells were collected on days
e1 and 0. The CD3þ or CD3/CD19þ cells were depleted by negative selection
by using the CliniMACS system (Miltenyi-BioTec, Bergisch-Gladbach,
Germany) according to the manufacturer’s instructions. If the patient
received a CD3-depleted graft without CD19 depletion, one dose of rituximab
was given at a dose of 375 mg/m2 after engraftment, usually around 3 to 4
weeks post-HHCT. In this study, 1 patient (case 1) received graft after
depletion of only CD3þ cells by CliniMACS. The remaining 11 patients
received grafts after in vitro depletion of CD3þ cells and the additional
depletion of CD19þ cells (4 with in vitro depletion of CD19þ cells and 7 with
in vivo depletion using rituximab posttransplantation).
Supportive Care
Patients were given antibiotics for bacterial prophylaxis, ﬂuconazole, or
micafungin for fungal prophylaxis, and acyclovir for viral prophylaxis. Since
July 2011, ganciclovir (5 mg/kg twice a day) has been used for cytomega-
lovirus (CMV) prophylaxis before HHCT, and forcarnet (60 mg/kg/day) has
been used for prophylaxis after transplantation and up until engraftment.
After engraftment, valganciclovir (25 mg/kg/day) was given until 100 days
posttransplantation and up until the recovery of CD4þ cell numbers
(>100 mL), according to the Tübingen strategy (Professor Handgretinger,
Univesity of Tübingen, Germany; personal communication). Beginning on
day 5, patients were treated with granulocyte colony-stimulating factor
(5 mg/kg/day) until an absolute neutrophil count 2,000 mLwas achieved for
3 consecutive days.
Posttransplantation Assessment
The day of neutrophil engraftment was deﬁned as the ﬁrst of 3 consec-
utive days onwhich the absolute neutrophil count exceeded 500 mL. Platelet
engraftment was deﬁned as the last of 7 consecutive days on which the
platelet count exceeded 20,000 mL without transfusion support. Donor
engraftment was determined by using DNA-based assays of short tandem
repeat sequences. Viral surveillance included weekly screening for CMV
using polymerase chain reaction and antigenemia assays and weekly
screening for Epstein-Barr virus using polymerase chain reaction. Preemp-
tive therapy with ganciclovir was initiated when positive results were ob-
tained in the polymerase chain reaction and antigenemia assays for CMV.
Acute GVHD (aGVHD)was graded according to standard criteria, and chronic
GVHD (cGVHD) was deﬁned as absent, limited, or extensive [13,14].
Deﬁnitions and Analysis
Early GF was deﬁned as graft loss occurring within 1month of HHCTand
included both primary GF (neutrophil counts did not exceed 500 mL at any
time point) and graft rejection (neutrophil counts initially exceeded 500 mL
but then decreased with complete loss of donor chimerism within 1 month
of HHCT). The date of the last follow-up for all patients was November
20, 2012.
RESULTS
Patient Characteristics
Nine of 12 patients weremale. Themedian age at the time
of transplantation was 13.5 years (range, 3.8 to 21.7 years).Of the 12 patients, 4 (cases 2, 3, 5, and 6) had very SAA. Two
patients (cases 2 and 7) were less transfused, whereas
the remaining 10 patients were heavily transfused, receiving
red blood cells >20 times and/or platelet preparations
>20 times. Additionally, 2 patients (cases 3 and 6) had dia-
betes mellitus at the time of transplantation. Four patients
received stem cells after in vitro depletion of both CD3þ and
CD19þ cells. Seven patients received CD3-depleted grafts and
then received rituximab post-HHCT to deplete B cells. The
remaining patient (case 1) received the CD3-depleted graft
without additional rituximab early post-transplantation.
Patient characteristics and transplantation outcomes are
shown in Table 1.
Nine of 12 patients had received IST before HHCT. Of three
patients who had not received IST, 2 (cases 2 and 6) were in
very SAA and had serious infections (one had multiple skin
abscesses, the other had a liver abscess) at the time of
transfer to our hospital. These two patients underwent HHCT
without delay after their infections had been controlled. For
the remaining patient (case 7), the parents refused to
consent to IST because rabbit ATG is known to be much less
effective than horse ATG, which is not available in Korea. The
median time from diagnosis to HHCT was 69 months (range,
7 to 135months); for 9 patients, there was more than 3 years
between diagnosis and HHCT.
Graft Composition
The mean T cell depletion of 15 transplantations,
including 3 salvage transplantations, was 3.3 log (range, 1.3
to 4.3 log), and the median dose of T cells after depletionwas
1.6  105/kg (range, .2 to 79.5). Add-back of T cells was per-
formed in 7 cases of 5 patients (cases 8 to 12 at the ﬁrst HHCT
and cases 7 and 9 at second HHCT) in an attempt to improve
engraftment. The data in Table 1 show the number of T cells
infused, including in the seven cases who received grafts
with added T cells. The median doses of infused CD34þ
and CD3þ cells were 5.36  106/kg (range, 3.0 to 9.4) and
1.14  106/kg (range, .16 to 7.95), respectively. Of the
12 patients, 5 received .1 to 1 106 T cells/kg, and 7 received
>1  106 T cells/kg.
Engraftment
Eleven of 12 patients achieved neutrophil engraftment at
a median of 10 days (range, 9 to 13 days) after HHCT. Two
patients (cases 3 and 7) experienced graft rejection, which
was documented 20 and 27 days post-HHCT, respectively.
One patient (case 9) failed to achieve primary engraftment.
All 3 received a second HHCT and achieved stable engraft-
ment. The ﬁnal engraftment rate was 100% (12/12). All 3
patients who experienced GF did not receive TBI as a
conditioning regimen. In contrast, none of the patients who
received the TBI-containing regimen experienced GF
(Figure 1A). None of the patients experienced late GF over
a median follow-up period of 14.3 months.
Acute and Chronic GVHD
Three of 9 assessable patients (excluding the 3 who
experienced early GF) developed aGVHD. Two patients
developed aGVHD  grade II on days þ7 and þ60, respec-
tively, and 1 developed grade III aGVHD on day þ8. None
showed grade IV aGVHD. All 3 had received grafts containing
>1  106 T cells/kg, and 2 had also received TBI (Figure 1B).
All 3 were successfully treated with steroids and calcineurin
inhibitors. All 3 patients who developed aGVHD received
a graft containing >1  106 T cells/kg. On the other hand,
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Figure 1. Incidence of GF and aGVHD (at least grade II) according to TBI and
T cell dose. (A) Graft failure (B) occurred in 3 patients in the non-TBI group.
(B) aGVHD (B) developed in 3 patients (1 in the non-TBI group and 2 in the
TBI group). All 3 patients had received a graft containing >1  106 T cells/kg.
Closed circle indicates no event.
H.J. Im et al. / Biol Blood Marrow Transplant 19 (2013) 754e759756none of the 5 patients who received <1  106 T cells/kg
developed aGVHD. Two of the 9 assessable patients devel-
oped cGVHD; 1 developed an extensive type that involved
the skin, oral mucosa, gastrointestinal tract, and eyes. This
patient remains on tacrolimus and steroids (long-term taper)
and shows good control of GVHD. There were no GVHD-
related deaths at the time of reporting.
Hematological Recovery and Chimerism Analysis
Eleven patients, including 3 patients who were rescued
with a second HHCT, showed sustained complete donor
chimerism and normal peripheral blood counts at the time of
analysis (Figure 2). One patient (case 4) showed mixed
chimerism, ranging from 81% to 97% donor cells. He also had
low platelet counts and was in need of platelet transfusion,
for which he received an infusion of CD34-selected stem cells
(1.26  106 CD34þ cells/kg and 1.99  103 CD3þ cells/kg)
from the same donor at day þ345. After this infusion, he is
alive and free of transfusion with stable mixed chimerism.
Second Haploidentical Transplantations
Three patients who experienced early GF received
a second HHCT. All achieved sustained engraftment after
conditioning with ﬂudarabine (150 mg/m2) and cyclophos-
phamide (100 mg/kg), with additional LD-TBI in 1 patient. All
three survived, with full donor chimerism and no req-
uirement for transfusion. Two patients (cases 7 and 9)
developed grade III aGVHD that involved the gut and received
additional steroids, which led to completed resolution.
Immune Reconstitution and Infections
The immune reconstitution of all 12 patients who had
sustained stable engraftment was examined, including
3 patients who received a successful salvage transplantation.
In all patients, the natural killer cell recovery was fast and
reached a normal value within 90 days posttransplantation.
However, the T and B cell recovery was delayed with
gradual increase and did not reach normal values until 1 year
posttransplantation. The median CD3þ, CD4þ, CD19þ, and
CD56þ cell counts around 90 days after the last HHCT were
438 cells/mL (range, 87 to 2302), 98 cells/mL (range, 7 to 182),
.93 cells/mL (range, 0 to 175), and 449 cells/mL (range, 5 to
1332), respectively. Around 180 days, these numbers were
Figure 2. Chimerism and transfusion requirements of 12 patients with SAA after HCT. Bars indicate the current length of follow-up after transplantation, with darker
bars indicating the transfusion-dependent period and lighter bars indicating the transfusion-independent period.
H.J. Im et al. / Biol Blood Marrow Transplant 19 (2013) 754e759 757519 cells/mL (range, 116 to 1,682), 196 cells/mL (range, 38 to
448), 47 cells/mL (range, 0 to 206), and 311 cells/mL (range, 18
to 1100), respectively. One year after the last HHCT, these
counts were 890 cells/mL (range, 251 to 1175), 373 cells/mL
(range, 87 to 442), 165 cells/mL (range, 12 to 618), and 242
cells/mL (range, 30 to 573), respectively.
The major infection noted was reactivation of CMV, which
occurred in 6 of 12 patients at a median of 53 days post-
transplantation. Two patients developed CMV retinitis at
day þ119 and day þ195, respectively. The vision of both
patients was saved by intraocular injection of ganciclovir
along with systemic treatment with ganciclovir or foscarnet.
Of the 8 patients who underwent HHCT after July 2011, which
is when CMV prophylaxis was started, only 3 experienced
transient reactivation without any development of disease.
One patient (case 1) developed posttransplantation lympho-
proliferative disorder at 68 days posttransplantation and was
successfully treated with rituximab and chemotherapy.
Hemorrhagic cystitis caused by the BK virus occurred in 5
patients, but all recovered completely after supportive care or
treatment with cidofovir. Three patients who had a severe
hemorrhagic cystitis with a high titer of BK virus in urine and
renal function deterioration received cidofovir intravenously,
at a dose of 5 mg/kg on a weekly basis. No serious bacterial or
fungal infections occurred during the study period. There
were no infection-related deaths.
Survival
As of November 2012, at a median follow-up period of
14.3 months (range, 4.1 to 40.7 months), all 12 patients were
alive and transfusion-independent.
DISCUSSION
The present study showed that HHCT with in vitro
depletion of CD3þ cells had a favorable outcome for all
12 children and adolescents with acquired SAA, most of
whom had a long history of SAA and had been heavily
transfused. Although T celledepleted grafts are commonlyused for patients with inherited bonemarrow failure [15-17],
this is the largest series of acquired SAA cases to be treated
with in vitro T celledepleted grafts to date.
The transplantation outcomes of patients with SAA,
including those receiving transplantations from matched
unrelated donors, have improved markedly [18-21].
However, the management of children or adolescents with
acquired SAA who lack a suitable related or unrelated donor
remains a challenge. The options include cord blood trans-
plantation or haploidentical transplantation from a mis-
matched family donor. Although several studies report the
use of cord blood transplantation for acquired SAA, high GF
rates are a major problem [22-24].
There are only a few reports of HHCT for SAA [6-8]. Some
studies of CD34-selected HHCT reported encouraging
outcomes, but the number of patients was too small to justify
a greater use of this approach [7,8]. We previously reported
our preliminary experiences with HHCT in 4 patients with
SAA, whowere included in the present study (cases 1-4) [12].
Recently, Xu et al. reported their experiencewith HHCT using
grafts without in vitro T cell depletion in 19 patients with
acquired SAA [25]. Although all 19 patients achieved primary
engraftment, 6 died from transplantation-related causes,
including GVHD, infection, and GF. The overall survival rate
was 64.5%. By contrast, in the present study, HHCT was
successful in 12 children and adolescents with acquired
SAA, none of whom had a suitable donor.
The ﬁrst obstacle to successful HHCT is engraftment
failure. GF after HHCT with T celledepleted grafts occurs
in 5% to 20% of patients [10,26,27]. In addition, compared
with patients with acute leukemia, GF is more common in
patients with nonmalignant disease, including SAA, espe-
cially heavily transfused cases [28-30]. In the present study,
3 of 12 patients experienced GF, including early graft rejec-
tion in 2 patients, and most of the patients were heavily
transfused before transplantation. Our initial trial used
a non-TBI conditioning regimen, but GF was experienced
by 1 of the 4 patients [12]. Thus, 6 of the subsequent 8
H.J. Im et al. / Biol Blood Marrow Transplant 19 (2013) 754e759758patients recruited to the present study received LD-TBI (400
cGy) as well. GF only occurred in the 2 patients who did not
receive TBI. Thus, none of the 3 patients who experienced GF
had received TBI as a conditioning regimen. Although all 3
patients were rescued by a second HHCT, it is desirable to
minimize the GF rate, particularly early-onset GF, which is
associatedwith complications such as a high risk of infection,
a long hospital stay, and high toxicity due to the additional
conditioning. Moreover, it is not always possible to ﬁnd
a suitable second donor. The Seattle group study showed that
TBI 200 cGy was sufﬁcient for successful engraftment of
transplantations from matched unrelated donors in patients
with SAA [31]. Given that the GF rate was somewhat high in
our initial trial, we introduced TBI at a dose of 400 cGy as
a conditioning regimen and will continue to use TBI 400 cGy
in our future conditioning regimen. If our future trial of this
protocol shows that it effectively prevents GF, we will
consider reducing the dose of TBI in a following study.
Of note, all cases of GF occurred early (within 30 days
posttransplantation) in our study, and there were no cases of
late GF with our immunosuppressant-weaning strategy.
However, a ﬁrm conclusion regarding the beneﬁcial effect of
haplo-mismatched transplantation on sustained engraft-
ment cannot be drawn from this small number of patients.
Poor graft function after transplantation has been re-
ported in patients with aplastic anemia, and it has been
shown that reinfusion of CD34-selected donor cells restores
graft function [32]. In the present study, 1 patient showed
poor graft function despite good donor chimerism. This
patient received an infusion of puriﬁed CD34þ cells from the
same donor and remains transfusion-free with mixed donor
chimerism.
The second barrier to successful HHCT is the development
of fatal GVHD. GVHD can be prevented by depleting donor
T cells from the graft. In the present study, 3 of the 9
assessable patients developed aGVHD  grade II; 1 of these
patients developed grade III. None developed grade IV
disease. All 3 had received a high dose of T cells (>1  106 T
cells/kg). Additionally, 2 of the 3 patients who received
a second HHCT developed grade III aGVHD. The higher
incidence of aGVHD after salvage transplantation may relate
to the fact that ATG was not used as part of the conditioning
regimen and a higher dose of T cells was present in the graft.
Overall, 5 of 12 patients in this study experienced aGVHD. All
5 patients had received higher doses of T cells (>1 106/kg).
This ﬁnding suggests that a high T cell dose in the graft may
be a risk factor for the development of GVHD.
To date, the optimal T cell dose for HHCT, low enough to
completely prevent severe GVHD but high enough to
completely avoid GF, has not been reported. A German study
suggested that a T cell content of<5104 cells/kg is safe and
effective for preventing GVHD after HLA nonidentical trans-
plantation without prophylaxis [33]. However, in that study,
4 patients experienced GF, and all 4 received grafts con-
taining<5104 CD3þ cells/kg. In addition, all 5 patients who
received>8 104 CD3þ cells/kg developed aGVHD, but none
experienced GF. In the present study, 5 patients received a T
cell dose of 1 to 10  105/kg, but none developed clinically
signiﬁcant aGVHD when treated with prophylactic calci-
neurin inhibitors and MMF.
Another practical issue to consider is that the reduction of
T cells is less effective with the recently developed depletion
method using CD3 monoclonal antibody than with the
CD34þ selection technique and frequently leads to residual
T cells in the graft that exceed the threshold of 5  104/kg.Therefore, it is not always possible to reduce the number of
residual T cells below 5  104/kg by depleting CD3þ cells.
Thus, immunosuppressive drugs are required to prevent
GVHD. Handgretinger and colleagues reported that depletion
of CD3/19þ Tcells was associatedwith an approximately 1-log
lower reduction in T cell numbers than positive selection of
CD34þ cells; therefore, pharmacologic GVHD prophylaxis was
necessary in most patients posttransplantation [10]. HHCT
using CD3-depleted grafts results in a higher incidence of
GVHD than that using positively selected CD34þ grafts,
possibly due to the variability of T cell depletion. It is unrea-
sonable to use the same intensity and duration of immune
suppression for GVHD prophylaxis regardless of the T cell
dose infused. None of our enrolled patients received grafts
containing<5104 Tcells/kg.Wewill conduct future trials in
which the dose of T cells will be ﬁxed at around 5  105/kg,
and tacrolimus and MMF will be used to prevent GVHD.
Infection is a major barrier to the wider application of
HHCT in patients who require transplantation but lack
a suitable donor. In the present study, 6 of 12 patients
experienced CMV reactivation, and 2 patients developed
CMV disease. Although both affected patients recovered from
CMV retinitis without any complications, this high preva-
lence of infection along with the delayed immune reconsti-
tution is a major problem that must be overcome. Given that
no CMV disease occurred after prophylaxis with ganciclovir,
foscarnet, and valganciclovir, our future protocol will include
this CMV prophylaxis, coupled with intensive surveillance
for viral infection.
In summary, the protocol wewill use in future studies will
include LD-TBI (400 cGy) as a conditioning regimen, in vitro
CD3 depletion, rituximab to deplete B cells, and a target
CD3þ cell dose of about 5 105/kg. Tacrolimus and MMF will
be used to prevent GVHD. Intensive viral surveillance and
CMV prophylaxis using ganciclovir, foscarnet, and valganci-
clovir will also be an important component of the protocol.
Although the present study is limited by the small number
of patients with SAA, the data demonstrate that the HHCT
protocol used yields excellent outcomes for children and
adolescents with acquired SAA. Therefore, HCT from hap-
loidentical family donors using in vitro depletion of CD3 cells
is a reasonable treatment option for children and adolescents
with acquired SAA. Our future trial will use a uniform
protocol and will help to solve many of the problems asso-
ciated with HHCT. It will also provide a valuable platform for
the further development of HHCT as a treatment for SAA.ACKNOWLEDGMENTS
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